Viewing Opinion | StockChase
Valeant Pharmaceuticals (VRX-T) opinion on 2017-09-12

Last Price Recorded: 18.8000 on 2017-11-17

ON STOCKCHASE SINCE Oct 2000

Consumer Products
DON'T BUY

Christine Poole
Valeant Pharmaceuticals was $17.600 at time of opinion
Owned : No

There is way too much debt on the balance sheet. The net debt to EBITDA is about 7X, very, very high. New management has come in, made some asset sales and paid off some debt that was coming due. The next tranche of debt is not due until 2020. However, there is very little visibility in terms of their products going forward. They are going to experience more genetic competition and pricing pressure in their dermatology division. It is hard to see how they are going to generate the necessary cash to start their debt repayments down the road.

BULLISH

All opinions for VRX-T (701)

127 BUY
19 BUY on WEAKNESS
68 COMMENT
253 DON'T BUY
30 HOLD
1 PARTIAL BUY
2 PARTIAL SELL
40 PAST TOP PICK
21 SELL
5 STRONG BUY
68 TOP PICK
25 WAIT
15 WATCH
27 WEAK BUY
View All

More experts covering VRX-T

SAVE
Add VRX-T to Watch List

All opinions for VRX-T (701)

127 BUY
19 BUY on WEAKNESS
68 COMMENT
253 DON'T BUY
30 HOLD
1 PARTIAL BUY
2 PARTIAL SELL
40 PAST TOP PICK
21 SELL
5 STRONG BUY
68 TOP PICK
25 WAIT
15 WATCH
27 WEAK BUY
View All

More experts covering VRX-T

SAVE
Add VRX-T to Watch List

No Comments.


You must be logged in to comment.

Successfully Saved Company